Waters Corporation reported second-quarter 2026 adjusted earnings of $3.05 per share, up 3.4% year over year and surpassing the Zacks Consensus Estimate by 1.33%. Revenues of $1.645 billion surged 113.4% from the year-ago quarter, topping the consensus mark by 1.25%, with organic revenues rising 9% in constant currency. The acquired Biosciences and Diagnostic Solutions businesses generated $817 million, exceeding guidance by $15 million. Reflecting broad-based strength, Waters raised its 2026 organic constant-currency revenue growth guidance to 7%-9% and lifted adjusted earnings guidance to $14.45-$14.65 per share. The company also expects total reported revenues between $6.415 billion and $6.476 billion for the year, with acquired businesses contributing approximately $3.045 billion. Management highlighted continued execution gains, including remediation of roughly 700 U.S. Diagnostic Solutions reagent rental contracts and plans to launch the FACSDiscover A7 Cell Analyzer on Sept. 15.
Waters CorporationWaters beats Q2 estimates and raises 2026 guidance
Opko Health Inc